Drug
HGP1705
HGP1705 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_3
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (66.7%)
Phase 31 (33.3%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers
NCT04324905
completedphase_3
Efficacy and Safety of HIP1601 Capsule
NCT04080726
unknownphase_1
Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations
NCT03372850
Clinical Trials (3)
Showing 3 of 3 trials
NCT04324905Phase 1
Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers
NCT04080726Phase 3
Efficacy and Safety of HIP1601 Capsule
NCT03372850Phase 1
Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3